In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin

Archives of Pharmacal Research

Volumn 30, Issue 8, 2007, Pages 991-1001

  Nie, Shufang ^a   Fan, Xiaowen ^a   Peng, Ying ^a   Yang, Xingang ^a   Wang, Chao ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Citric acid; Hydroxypropyl cyclodextrin; Improving dissolution rate; Inclusion complexes; Vinpocetine

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTIHYPERTENSIVE AGENT; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; UNCLASSIFIED DRUG; VINCA ALKALOID; VINPOCETINE;

ANIMAL; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; INFRARED SPECTROPHOTOMETRY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; RABBIT; SOLUBILITY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMPOUNDING; EXCIPIENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RABBITS; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; VINCA ALKALOIDS; X-RAY DIFFRACTION;

EID: 34548706619     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02993968     Document Type: Article

References (19)

1. Amato, M. E., Lipkowitz, K. B., Lombardo, G. M., and Pappalardo, G. C., High-field NMR spectroscopic techniques combined with molecular dynamics simulations for the study of the inclusion complexes of α- and β-cyclodextrins with the cognition activator 3-phenoxypyridine sulphate (CI-844). Magn. Reson. Chem., 36, 693-705 (1998).
2. Bekers, O., Uijtendaal, E.V., Beijnen, J.H., Buit, A., and Underberg, W. J. M., Cyclodextrins in the pharmaceutical field. Drug Dev. Ind. Pharm., 17, 1503-1549 (1991).
3. Brewster, M., Parental safety and application of 2-hydroxypropyl-β- cyclodextrin, In: Duchêne, D. (Ed.), New Trends in Cyclodextrin and Derivatives, Editions de Santé, Paris, pp. 313-351, (1991).
4. Csanda, E., Harcos, P., Bácsy, Z., Berghammer, R., and Kenéz, J., Ten Years of Experience with Cavinton. Drug Dev. Res., 14, 185-187 (1988).
5. Enrico, R., Lajos, S., and József, S., Drug/cyclodextrin/hydroxy acid multicomponent systems: properties and pharmaceutical applications. J. Pharm. Sci., 89, 1-8 (2000).
6. Erden, N. and Celebi, N., A study of the inclusion complex of naproxen with β-cyclodextrin. Int. J. Pharm., 48, 83-89 (1988).
7. Esclusa-Diaz, M., Torres-Labandeira, J., Kata, M., and Vila-Jato, J., Inclusion complexation of glibenclamide with 2-hydroxypropyl-β-cyclodextrin in solution and in solid state. Eur. J. Pharm. Sci., 1, 291-296 (1994).
8. Grandt, R., Beitinger, R., Schaltenbrand, R., and Braun, W., Vinpocetine pharmacokinetics in elderly subjects. Arzneimittelforschung./Drug Res., 39, 1599-1602 (1989).
9. Hassan, M., Suleiman, M., and Najib, N., Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrin. Int. J. Pharm., 58, 19-24 (1990).
10. Higuchi, T. and Connors, K., Phase-solubility techniques, Adv. Anal. Chem. Instrum., 4, pp. 117-212, (1965).
11. Kata, M. and Gyorgy, E., Spruheinbettung von vinpocetine mit β-cyclodextrin. Pharmazie, 37, 386-387 (1982).
12. Kata, M. and Lukács, M., Enhancement of solubility of vinpocetine base with γ-cyclodextrin. Pharmazie, 41, 151-152 (1986).
13. Kiss, B. and Karpati, E., Mechanism of action of vinpocetine. Acta. Pharm. Hung., 66, 213-24 (1996).
14. Laura, R., Thorsteinn, L., Domingos, F., and Francisco, V., Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-Cyclodextrin binary and ternary complexes. Chem. Pharm. Bull., 51, 914-922 (2003).
15. Lohmann, A., Dingler, E., Sommer, W., Schaffler, K., Wober, W., and Schmidt, W., Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung., 42, 914-917 (1992).
16. Másson, M., Loftsson, T., Jónsdóttir, S., Fridriksdóttir, H., and Peterson, D. S., Stabilization of ionic drugs through complexation with non-ionic and ionic cyclodextrins. Int. J. Pharm., 164, 45-55 (1998).
17. Mura, P., Adragna, E., Rabasco, A., Moyano, J., Pérez-Martinez, J. M., and Arias, J. G., Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin. Drug Dev. Ind. Pharm., 25, 279-287 (1999).
18. Pitha, J. and Pitha, J., Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci., 74, 987-990 (1985).
19. Szejtli, J., Medicinal applications of cyclodextrins. Med. Res. Rev., 14, 353-386 (1994).